NewsBenzinga정정: BRC 그룹 홀딩스, 3분기 주당순손실 5.98달러로 전년 동기 2.97달러 대비 감소, 매출 3,302만 8천 달러로 전년 동기 2억 7,787만 1천 달러 대비 감소 정정: BRC 그룹 홀딩스, 3분기 주당순손실 5.98달러로 전년 동기 2.97달러 대비 감소, 매출 3,302만 8천 달러로 전년 동기 2억 7,787만 1천 달러 대비 감소 Benzinga 2026.11.05 23:25 (GMT+0) Open on Benzinga Other news Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate Stock Market: Will S&P 500 Open Up or Down Today? IREN Mining Revenue Falls 58% as AI Sales Reach $200 Million
Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets
Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors
Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events
Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate
